The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.
via Education - Latest News http://www.prlog.org/12229954-napsr-news-potential-new-drug-for-some-patients-with-treatment-resistant-lung-cancer.html
via Education - Latest News http://www.prlog.org/12229954-napsr-news-potential-new-drug-for-some-patients-with-treatment-resistant-lung-cancer.html
No comments:
Post a Comment